Establishment of a GDP-mannose 4,6-dehydratase (GMD) knockout host cell line: A new strategy for generating completely non-fucosylated recombinant therapeutics

Journal of Biotechnology

Volumn 130, Issue 3, 2007, Pages 300-310

  Kanda, Yutaka ^a   Imai Nishiya, Harue ^a   Kuni Kamochi, Reiko ^a   Mori, Katsuhiro ^a   Inoue, Miho ^a   Kitajima Miyama, Kazuko ^a   Okazaki, Akira ^a   Iida, Shigeru ^a   Shitara, Kenya ^a   Satoh, Mitsuo ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); GDP fucose synthesis; GDP mannose 4,6 dehydratase (GMD); GMD knockout; Non fucosylated therapeutics production; Oligosaccharide fucosylation pathway

Indexed keywords

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC); FUCOSE SYNTHESIS; NON FUCOSYLATED THERAPEUTICS PRODUCTION; OLIGOSACCHARIDE FUCOSYLATION PATHWAYS;

ANTIBODIES; CELL CULTURE; CYTOTOXICITY; GROWTH KINETICS; OLIGOSACCHARIDES; RNA; SYNTHESIS (CHEMICAL);

ENZYME KINETICS;

FUCOSE; FUCOSYLTRANSFERASE; GUANOSINE DIPHOSPHATE FUCOSE; GUANOSINE DIPHOSPHATE MANNOSE; GUANOSINE DIPHOSPHATE MANNOSE 4,6 DEHYDRATASE; HYDROLYASE; MESSENGER RNA; OLIGOSACCHARIDE; RECOMBINANT PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL GROWTH; CELL LINE; CELL STRUCTURE; CHO CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CULTURE MEDIUM; FUCOSYLATION; GENE; GENE EXPRESSION; GENETIC RECOMBINATION; GMD GENE; KNOCKOUT GENE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PRODUCTIVITY; PROTEIN SYNTHESIS;

ANIMALS; ANTIGENS, CD20; BIOTECHNOLOGY; CHO CELLS; CRICETINAE; CRICETULUS; CULTURE MEDIA, SERUM-FREE; DNA, COMPLEMENTARY; FUCOSE; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; HYDRO-LYASES; IMMUNOGLOBULIN G; MICE; MONOSACCHARIDE TRANSPORT PROTEINS; OLIGOSACCHARIDES; PLANT LECTINS; RECOMBINANT PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING;

CRICETULUS GRISEUS;

EID: 34250369571     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2007.04.025     Document Type: Article

References (30)

1. Becker D.J., and Lowe J.B. Fucose: biosynthesis and biological function in mammals. Glycobiology 13 (2003) 41R-53R
2. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., and Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 99 (2002) 754-758
3. Clynes R.A., Towers T.L., Presta L.G., and Ravetch J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6 (2000) 443-446
4. Ferrara C., Brunker P., Suter T., Moser S., Puntener U., and Umana P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1,4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol. Bioeng. 93 (2006) 851-861
5. Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., Oliviero B., Ballardini B., Da Prada G., Zambelli A., and Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 10 (2004) 5650-5655
6. Hajjar K.A., and Reynolds C.M. alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells. J. Clin. Invest. 93 (1994) 703-710
7. Handford M., Rodriguez-Furlan C., and Orellana A. Nucleotide-sugar transporters: structure, function and roles in vivo. Braz. J. Med. Biol. Res. 39 (2006) 1149-1158
8. Hirschberg C.B. Golgi nucleotide sugar transport and leukocyte adhesion deficiency II. J. Clin. Invest. 108 (2001) 3-6
9. Kanda Y., Yamada T., Mori K., Okazaki A., Inoue M., Kitajima-Miyama K., Kuni-Kamochi R., Nakano R., Yano K., Kakita S., Shitara K., and Satoh M. Comparison of biological activity among non-fucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2006) 104-118
10. Kanda Y., Yamane-Ohnuki N., Sakai N., Yamano K., Nakano R., Inoue M., Misaka H., Iida S., Wakitani M., Konno Y., Yano K., Shitara K., Hosoi S., and Satoh M. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94 (2006) 680-688
11. Mori K., Kuni-Kamochi R., Yamane-Ohnuki N., Wakitani M., Yamano K., Imai H., Kanda Y., Niwa R., Iida S., Uchida K., Shitara K., and Satoh M. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. Biotechnol. Bioeng. 88 (2004) 901-908
12. Nakamura K., Tanaka Y., Fujino I., Hirayama N., Shitara K., and Hanai N. Dissection and optimization of immune effector functions of humanized anti-ganglioside GM2 monoclonal antibody. Mol. Immunol. 37 (2000) 1035-1046
13. Niwa R., Shoji-Hosaka E., Sakurada M., Shinkawa T., Uchida K., Nakamura K., Matsushima K., Ueda R., Hanai N., and Shitara K. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 64 (2004) 2127-2133
14. Pastuszak I., Ketchum C., Hermanson G., Sjoberg E.J., Drake R., and Elbein A.D. GDP-l-fucose pyrophosphorylase. Purification, cDNA cloning, and properties of the enzyme. J. Biol. Chem. 273 (1998) 30165-30174
15. Presta L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Avd. Drug Deliv. Rev. 58 (2006) 640-656
16. Reitman M.L., Trowbridge I.S., and Kornfeld S. Mouse lymphoma cell lines resistant to pea lectin are defective in fucose metabolism. J. Biol. Chem. 255 (1980) 9900-9906
17. Ripka J., Adamany A., and Stanley P. Two Chinese hamster ovary glycosylation mutants affected in the conversion GDP-mannose to GDP-fucose. Biochem. Biophys. Arch. 249 (1986) 533-545
18. Satoh M., Iida S., and Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6 (2006) 1161-1173
19. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity. J. Biol. Chem. 277 (2002) 26733-26740
20. Shinkawa T., Nakamura K., Yamane N., Shoji-Hosaka E., Kanda Y., Sakurada M., Uchida K., Anazawa H., Satoh M., Yamasaki M., Hanai N., and Shitara K. The absence of fucose but not the presence of galactose or bisecting GlcNAc of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem. 278 (2003) 3466-3473
21. Smith P.L., Myers J.T., Rogers C.E., Zhou L., Petryniak B., Becker D.J., Homeister J.W., and Lowe J.B. Conditional control of selectin ligand expression and global fucosylation events in mice with a targeted mutation at the FX locus. J. Cell. Biol. 158 (2002) 801-815
22. Somoza J.R., Menon S., Schmidt H., Joseph-McCarthy D., Dessen A., Stahl M.L., Somers W.S., and Sullivan F.X. Structural and kinetic analysis of Escherichia coli GDP-mannose 4,6 dehydratase provides insights into the enzyme's catalytic mechanism and regulation by GDP-fucose. Structure 8 (2000) 123-135
23. Stanley P., Caillibot V., and Siminovitch L. Selection and characterization of eight phenotypically distinct lines of lectin-resistant Chinese hamster ovary cell. Cell 6 (1975) 121-128
24. Tonetti M., Sturla L., Bisso A., Benatti U., and De Flora A. Synthesis of GDP-l-fucose by the human FX protein. J. Biol. Chem. 271 (1996) 27274-27279
25. Tsuda E., Kawanishi G., Ueda M., Masuda S., and Sasaki R. The role of carbohydrate in recombinant human erythropoietin. Eur. J. Biochem. 188 (1990) 405-411
26. Urlaub G., and Chasin L.A. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. U.S.A. 77 (1980) 4216-4220
27. Webb N.A., Mulichak A.M., Lam J.S., Rocchetta H.L., and Garavito R.M. Crystal structure of a tetrameric GDP-D-mannose 4,6-dehydratase from a bacterial GDP-d-rhamnose biosynthetic pathway. Protein Sci. 13 (2004) 529-539
28. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (2004) 1393-1398
29. Yamane-Ohnuki N., Kinoshita S., Inoue-Urakubo M., Kusunoki M., Iida S., Nakano R., Wakitani M., Niwa R., Sakurada M., Uchida K., Shitara K., and Satoh M. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol. Bioeng. 87 (2004) 614-622
30. Yurchenco P.D., and Atkinson P.H. Fucosyl-glycoprotein and precursor polls in HeLa cells. Biochemistry 14 (1975) 3107-3114